

2023-24 SPSN Report #9 Epi-weeks 19 to 28: May 5 to July 13, 2024


Overall, between early-May and mid-July 2024, ongoing spring-summer monitoring by the SPSN has shown only sporadic low-level detection of influenza or RSV, with increased levels of entero/rhinovirus and SARS-CoV-2.

Table 1. Respiratory pathogen detections overall and by province, epi-weeks 19 to 28 (May 5 to July 13) 2024

	Overall	British Columbia (BC)	Alberta	Ontario	Quebec
	N = 1217	N = 159	N = 178	N = 379	N = 501
	n (% positive)	n (% positive)	n (% positive)	n (% positive)	n (% positive)
At least one respiratory pathogen detected	642 (53%)	81 (51%)	90 (51%)	207 (55%)	264 (53%)
Influenza viruses	59 (5%)	11 (7%)	9 (5%)	9 (2%)	30 (6%)
Influenza A ^a	22 (2%)	8 (5%)	5 (3%)	5 (1%)	4 (1%)
Influenza B	37 (3%)	3 (2%)	4 (2%)	4 (1%)	26 (5%)
SARS-CoV-2	119 (10%)	18 (12%)	34 (19%)	39 (10%)	28 (6%)
Entero/rhinoviruses (EV/RV)	258 (21%)	24 (15%)	30 (17%)	90 (24%)	114 (23%)
Respiratory syncytial virus	12 (10/)	0 (0%)	0 (0%)	2 (1%)	10 (2%)
(RSV)	12 (1%)				
Other ^b	223 (18%)	33 (21%)	20 (11%)	80 (21%)	90 (18%)

^a Of influenza A viruses subtyped overall in epi-weeks 19-28 (n=22), 14/22 (64%) were A(H1) and 8/22 (36%) were A(H3).

Figure 1. Weekly testing and percent positivity among SPSN specimens overall*, epi-weeks 44-28, 2023-24



^{*} All values for the most recent epi-week are subject to change. Among SPSN specimens overall, a total of 252 were diagnosed with co-infections, mostly involving EV/RV and another respiratory virus. In British Columbia and Quebec, multiplex testing additionally includes *Mycoplasma pneumoniae*, for which 22/4292 (0.5%) were positive since epi-week 44, including 14 children and 8 adults.

Version date: August 1, 2024

^b Other overall include parainfluenza (115/1214; 9%), seasonal coronaviruses (20/1214; 2%), human metapneumovirus (71/1214; 6%), and adenovirus (22/1213; 2%). In BC and Quebec, multiplex testing additionally includes *Mycoplasma pneumoniae*. In BC, 1/159 (0.6%) was Mycoplasma positive, including 1 child. In Quebec, 5/501 (1%) were Mycoplasma positive, including 4 children and 1 adult.



b) Alberta a) British Columbia 100 Total tests (N=1361) 100 90 100 Total tests (N=1170) Influenza positivity (196/1357; 14%) Influenza positivity (236/1169; 20%) 90 90 90 80 Influenza A positivity (168/1357; 12%) - Influenza A positivity (176/1169: 15%) Influenza B positivity (28/1357; 2%) · Influenza B positivity (60/1169; 5%) 80 80 80 70 EV/RV positivity (208/1359; 15%) SARS-CoV-2 positivity (134/1167; 11%) SARS-CoV-2 positivity (94/1345; 7%) 70 70 EV/RV positivity (137/1164; 12%) 70 RSV positivity (92/1360; 7%) 60 RSV positivity (31/1168; 3%) Number of tests Other positivity (236/1359; 17%) 60 **% Positivity** 50 40 60 **%** Other positivity (142/1166; 12%) 50 50 **E** 40 40€ 30 30 30 30 20 20 20 20 10 10 10 10 0 0 44 46 48 50 52 2 4 6 8 10 12 14 16 18 20 22 24 26 28 44 46 48 50 52 2 4 6 8 10 12 14 16 18 20 22 24 26 28 2023-24 epi-week 2023-24 epi-week c) Ontario d) Quebec 160 100 Total tests (N=2933) 350 100 Total tests (N=4133) Influenza positivity (677/2933; 23%) Influenza positivity (1002/4116; 24%) ---- Influenza A positivity (493/2933; 17%) 90 90 - Influenza A positivity (741/4116; 18%) 140 ······ Influenza B positivity (184/2933; 6%) 300 Influenza B positivity (262/4116; 6%) EV/RV positivity (342/2933; 12%) 80 80 SARS-CoV-2 positivity (413/4104; 10%) SARS-CoV-2 positivity (207/2933; 7%) 120 EV/RV positivity (377/4109; 9%) 250 RSV positivity (155/2933; 5%) 70 70 RSV positivity (256/4119; 6%) Number of tests Other positivity (464/2933; 16%) Number of tests Other positivity (634/4108; 15%) 60 **Positivity** 40 **Positivity** 60% 200 50 **E** 150 40₹ 30 30 100 40 20 20 50 20 10 10 0 0 44 46 48 50 52 2 4 6 8 10 12 14 16 18 20 22 24 26 28 44 46 48 50 52 2 4 6 8 10 12 14 16 18 20 22 24 26 28 2023-24 epi-week 2023-24 epi-week

Figure 2. Weekly testing and percent positivity among SPSN specimens by province*, epi-weeks 44-28, 2023-24

Table 2. Additional resources for respiratory pathogen surveillance

BCCDC - Respiratory Disease Dashboard	Australian Influenza Surveillance Reports
PHAC - FluWatch Surveillance PHAC - Human Emerging Respiratory Pathogens Bulletins	New Zealand Institute of Environmental Science and Research (ESR) - Acute Respiratory Illness Infections Dashboard
United States Washington State - Influenza Updates California State - Influenza and Respiratory Disease Surveillance Report CDC - Weekly Influenza Surveillance Report	World Health Organization Global Influenza Updates Weekly Epidemiological Record Recommendations for Influenza Vaccine Composition
Europe Joint ECDC—WHO/Europe - Flu News	World Organization for Animal Health OFFLU - Animal influenza

Oceania

Canada

^{*} All values for the most recent epi-week are subject to change.